| Old Articles: <Older 3301-3310 Newer> |
 |
Chemistry World December 2006 Derek Lowe |
Opinion: In the Pipeline A look at the story behind the growing investment by western companies in medicinal chemistry research in China.  |
The Motley Fool November 27, 2006 Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.  |
The Motley Fool November 27, 2006 Billy Fisher |
Banner Year for Meridian Bioscience The little diagnostic-test-kit maker that could. The company has seen its stock price appreciate 27% over the past twelve months, and it recently reported a record fiscal 2006.  |
The Motley Fool November 27, 2006 Brian Lawler |
Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note.  |
The Motley Fool November 24, 2006 Brian Lawler |
Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note.  |
The Motley Fool November 22, 2006 Brian Lawler |
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.  |
The Motley Fool November 22, 2006 Brian Lawler |
Actelion's Adept Acquisition The pharmaceutical buys CoTherix, streamlining sales of both firms' PAH treatments. Investors, take note.  |
The Motley Fool November 22, 2006 Brian Lawler |
Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news.  |
Inc. November 2006 Elaine Appleton Grant |
Gold in Oldies For sale: A small assisted living residence, near Atlanta, that the owner built for Mom.  |
The Motley Fool November 20, 2006 Brian Lawler |
One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one.  |
| <Older 3301-3310 Newer> Return to current articles. |